1. High MMP‑26 expression in glioma is correlated with poor clinical outcome of patients
- Author
-
Yong Gao Mou, Jian‑Gui Guo, Cheng Cheng Guo, Xiu‑Yu Cai, and Zhen Qiang He
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,astrocytic glioma ,03 medical and health sciences ,0302 clinical medicine ,MMP-26 ,Glioma ,Internal medicine ,medicine ,Clinical significance ,Oncogene ,Proportional hazards model ,business.industry ,Cancer ,Articles ,Cell cycle ,medicine.disease ,Molecular medicine ,030104 developmental biology ,030220 oncology & carcinogenesis ,immunohistochemistry ,Immunohistochemistry ,prognosis ,business - Abstract
To date the management of glioma remains a great challenge in cancer therapy worldwide. The identification of novel diagnostic and therapeutic methods is required. Although there is data indicating that matrix metalloproteinase (MMP)-26 serves an important role in many human cancer types, its clinical significance in glioma remains uncertain. The present study aimed to evaluate MMP-26 expression in human astrocytic glioma specimens, and investigate its role and significance in the progression of astrocytic glioma. Immunohistochemistry was performed to assess MMP-26 expression in astrocytic glioma tissues. The levels of MMP-26 expression and its relevance to the clinicopathological features and prognostic factors in patients with astrocytic glioma patients were then investigated. The results demonstrated that MMP-26 expression was significantly assocaited with the World Health Organization grade (P
- Published
- 2018
- Full Text
- View/download PDF